Intestinal receptor targeting for peptide delivery: An expert's personal perspective on reasons for failure and new opportunities

Therapeutic Delivery

Volumn 2, Issue 12, 2011, Pages 1575-1593

  Russell Jones, Gregory ^a  

^a Mentor Pharmaceutical Consulting Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FC RECEPTOR; INSULIN; INSULIN RECEPTOR; LACTOFERRIN; NANOPARTICLE; TRANSFERRIN;

CELL WALL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; EVOLUTIONARY ADAPTATION; HUMAN; INTESTINE EPITHELIUM CELL; INTESTINE WALL; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; TRANSCYTOSIS; TRANSPORT KINETICS;

EID: 81255156928     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.129     Document Type: Review

References (259)

1. Henin J, Tajkhorshid E, Schulten K, Chipot C. Diffusion of glycerol through Escherichia coli aquaglyceroporin GlpF. Biophys. J. 94, 832-839 (2008) (Pubitemid 351187687)
2. Wang Y, Cohen J, Boron WF, Schulten K, Tajkhorshid E. Exploring gas permeability of cellular membranes and membrane channels with molecular dynamics. J. Struct. Biol. 157, 534-544 (2007). (Pubitemid 46321519)
3. Yu J, Yool AJ, Schulten K, Tajkhorshid E. Mechanism of gating and ion conductivity of a possible tetrameric pore in aquaporin-1. Structure 14, 1411-1423 (2006). (Pubitemid 44339604)
4. Törnroth-Horsefield S, Wang Y, Hedfalk K et al. Structural mechanism of plant aquaporin gating. Nature 439, 688-694 (2006). (Pubitemid 43237610)
5. Wang Y, Schulten K. Tajkhorshid E. What makes an aquaporin a glycerol channel: A comparative study of AqpZ and GlpF. Structure 13,1107-1118 (2005). (Pubitemid 41111479)
6. Stahl A, Hirsch DJ, Gimeno RE et al. Identification of the major intestinal fatty acid transport protein. Mol. Cell 4, 299-308 (1999). (Pubitemid 29499783)
7. Ganapathy V, Thangaraju M, Gopal E et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 10, 193-199 (2008).
8. Adibi SA. The oligopeptide transporter (PepT1) in human intestine: biology and function. Gastroenterology 113, 332-340 (1997). (Pubitemid 27281791)
9. Adibi SA, Soleimanpour MR. Functional characterization of dipeptide transport system in human jejunum. J. Clin. Invest. 53, 1368-1374 (1974).
10. Adibi SA, Morse EL, Masilamani SS, Amin PM. Evidence for two different modes of tripeptide disappearance in human intestine. Uptake by peptide carrier systems and hydrolysis by peptide hydrolases. J. Clin. Invest. 56, 1355-1363 (1975).
11. Kramer W. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery. Biol. Chem. 392(1-2), 77-94 (2011).
12. Kim H-R, Park S-W, Cho H-J et al. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharm. Res. 56, 224-236 (2007). (Pubitemid 47321206)
13. Zimnicka AM, Maryon EB, Kaplan JH. Human copper transporter hCTR1 mediates basolateral uptake of copper into enterocytes: implications for copper homeostasis. J. Biol. Chem. 282(36), 26471-26480 (2007). (Pubitemid 47443790)
14. Hastings RH, Folkesson HG, Matthay MA. Mechanisms of alveolar protein clearance in the intact lung. Am. J. Physiol. Lung Cell Mol. Physiol. 286(4), L679-L689 (2004). (Pubitemid 38365050)
15. Zaki NM, Tirelli N. Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Exp. Opin. Drug Deliv. 7(8), 895-913 (2010)
16. Predescu SA, Predescu DN, Malik AB. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 293(4), L823-L842 (2007). (Pubitemid 47572231)
17. Simionescu M, Popov D, Sima A. Endothelial transcytosis in health and disease. Cell Tissue Res. 335(1), 27-40(2009).
18. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res.19(5), 569-577 (2002). (Pubitemid 34553662)
19. Saito A, Sato H, Iino N, Takeda T. Molecular mechanisms of receptor-mediated endocytosis in the renal proximal tubular epithelium. J. Biomed. Biotechnol. doi:10.1155/2010/403272 (2010) (Epub ahead of print).
20. Christensen EI, Verroust PJ, Nielsen R. Receptor-mediated endocytosis in renal proximal tubule. Pflugers Arch. 458(6), 1039-1048 (2009).
21. 12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. Am. J. Physiol. Renal Physiol. 291(1), F22-F36 (2006). (Pubitemid 43945932)
22. Rajadhyaksha M, Boyden T, Liras J, El-Kattan A, Brodfuehrer J. Current advances in delivery of biotherapeutics across the blood-brain barrier. Curr. Drug Discov. Technol. 8(2), 87-101 (2011).
23. Wang YY, Lui PC, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 1(6), 983-993 (2009).
24. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Exp. Opin. Drug Deliv. 2(2), 299-309 (2005). (Pubitemid 41130884)
25. Soni V, Jain A, Khare P, Gulbake A, Jain SK. Potential approaches for drug delivery to the brain: past, present, and future. Crit. Rev. Ther. Drug Carrier Syst. 27(3), 187-236 (2010).
26. Chamberlain MC. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability. Exp. Rev. Neurother. 10(4), 547-561 (2010).
27. Subramanian N, Adiga PR. Simultaneous purification of biotin-binding proteins-I and -II from chicken egg yolk and their characterization. Biochem. J. 308, 573-577 (1995).
28. Hytönen VP, Määttä JA, Niskanen EA et al. Structure and characterization of a novel chicken biotin-binding protein A (BBP-A). BMC Structural Biology 7, 8 (2007).
29. Murphy CV, Adiga PR. Purification of biotin-binding protein from chicken egg yolk and comparison with avidin. BBA, 786, 222-30 (1984).
30. Kim JG, Vallet JL. Secreted and membrane forms of folate-binding protein occur sequentially during pregnancy in swine. Biol. Reprod. 71, 1214-1217 (2004).
31. Vallet JL, Klemcke HG, Christenson PK. Interrelationships among conceptus size, uterine protein secretion, fetal erythropoiesis and uterine capacity. J. Anim. Sci. 80, 729-737 (2002). (Pubitemid 41138521)
32. Shaw DT, Rozeboom DW, Hill GM. Booren AM. Link JE. Impact of vitamin and mineral supplement withdrawal and wheat middling inclusion on finishing pig growth performance, fecal mineral concentration, carcass characteristics, and the nutrient content and oxidative stability of pork. J. Anim. Sci. 80, 2920-2930 (2002). (Pubitemid 41132945)
33. Zanette D, Monaco HL, Zanotti G, Spadon P. Crystallization of hen eggwhite riboflavin-binding protein. J. Mol. Biol. 180, 1185-1187 (1984).
34. Monaco HL. Crystal structure of chicken riboflavin binding protein. Embo. 16, 1475-1483 (1997). (Pubitemid 27151942)
35. Adiga PR, Visweswariah SS, Karande A. Kuzhandkaivelu N. Biochemical and immunological characteristics of riboflavin carrier protein. J. Biosci. 13, 87-104 (1988).
36. Adiga PR, Subramanian S, Rao J, Kumar M. Prospects of riboflavin carrier protein (RCP) as an antifertility vaccine in male and female mammals. Human Reprod. Update. 3, 325-324 (1997)
37. Muniyappa K, Adiga PR. Isolation and characterization of thiamin-binding protein from chicken egg white. Biochem. J. 177, 887-94 (1979). (Pubitemid 9150735)
38. Muniyappa K. Adiga PR. Nature of the thiamin binding protein from chicken egg yolk. Biochem. J. 193, 678-685 (1981).
39. Pácha J. Development of intestinal transport function in mammals. Physiol. Rev. 80, 1633-1667 (2000).
40. Widera A, Kim KJ, Crandall ED, Shen WC. Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers. Pharm. Res. 20, 1231-1238 (2003). (Pubitemid 36951848)
41. Matsuura M, Okazaki K, Nishio A et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterol. 128, 975-986 (2005). (Pubitemid 40523548)
42. Cummins AG, Thompson FM. Effect of breast milk and weaning on epithelial growth of the small intestine in humans. Gut 51, 748-754 (2002). (Pubitemid 35216868)
43. Taillon C, Andreasen A. Veterinary nutraceutical medicine. Can. Vet. J. 41, 231-234 (2000) (Pubitemid 30182872)
44. Montaner B, Asbert M, Perez-Tomas R. Immunolocalization of transforming growth factor-a and epidermal growth factor receptor in the rat gastroduodenal area. Dig. Dis Sci. 44, 1408-1416 (1999). (Pubitemid 29404306)
45. Stirling CMA, Charleston B, Takamatsu H et al. Characterization of the porcine neonatal Fc receptor -potential use for trans-epithelial protein delivery. Immunology 114, 542-553 (2005). (Pubitemid 40478148)
46. Bies C, Lehr CM, Woodley JF. Lectin-mediated drug targeting: history and applications. Adv. Drug Deliv. Rev. 56, 425-435 (2004). (Pubitemid 38210415)
47. Woodley JF. Lectins for gastrointestinal targeting -15 years on. J. Drug Target. 7(5), 325-333 (2000)
48. Carreno-Gómez B, Woodley JF, Florence AT. Studies on the uptake of tomato lectin nanoparticles in everted gut sacs. Int. J. Pharm. 183, 7-11 (1999). (Pubitemid 29248818)
49. Naisbett B, Woodley J. Binding of tomato lectin to the intestinal mucosa and its potential for oral drug delivery. Biochem. Soc. Trans. 18(5), 879-880 (1990). (Pubitemid 20359344)
50. Grant G, Greer F, Mackenzie NH, Pusztai A. Nutritional response of mature rats to kidney bean (Phaseolus vulgaris) lectins. J. Sci. Food Agric. 36, 409-414 (1985).
51. Pusztai A, Clarke EN, Grant G. King TP. The toxicity of Phaseolus vulgaris lectin. Nitrogen balance and immunochemical studies. J. Sci. Food Agric. 2, 1037-1047 (1981)
52. Begbie R. King TP. The interaction of dietary lectin with porcine small intestine and the production of lectin-specific antibodies. In: Lectins: Biomedical Perspectives (Volume 4). Bog-Hansen TC, Breborowiez J (Eds). Taylor&Francis, Bristol, PA, USA, 15-27 (1985).
53. Lorenzsonn V, Olsen WA. In vivo responses of rat intestinal epithelium to intraluminal dietary lectins. Gastroenterol 82, 838-848 (1982) (Pubitemid 12142525)
54. Ovtsharoff W, Ichev K. Localization of lectin binding sites on rat intestinal microvillous membrane. Acta Histochem. 74, 21-24 (1984) (Pubitemid 14129884)
55. de Aizpurua HJ, Russell-Jones, GJ. Oral vaccination: identification of classes of proteins which provoke an immune response upon oral feeding. J. Exp. Med. 167, 440-451 (1987). (Pubitemid 18073646)
56. Lavelle EC, Grant G, Pfuller U, O'Hagan DT. Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract. J. Drug Target. 12(2), 89-95 (2004). (Pubitemid 38786917)
57. Clement F, Venkatesh YP. Dietary garlic (Allium sativum) lectins, ASA I and ASA II, are highly stable and immunogenic. Int. Immunopharmacol. 10, 1161-1169 (2010).
58. Haas H, Falcone FH, Schramm G et al. Dietary lectins can induce in vitro release of IL-4 and IL-13 from human basophils. Eur. J. Immunol. 29, 918-927 (1999). (Pubitemid 29119072)
59. Smith MW, Thomas NW, Jenkins PG et al. Selective transport of microparticles across Peyer's Patch follicle-associated M cells from mice and rats. Exp. Physiol. 80, 735-743 (1995)
60. O'Hagan DT. Intestinal translocation of particulates -implications for drug and antigen delivery. Adv. Drug Del. Rev. 5, 265-285 (1990).
61. Lomotan EA, Brown KA, Speaker TJ, Offita PA. Aqueous-based microcapsules are detected primarily in gut-associated dentritic cells after oral inoculation of mice. Vaccine 15, 1959-1962 (1997). (Pubitemid 27504694)
62. Gabor F, Wirth M. Lectin-mediated bioadhesion: proteolytic stability and binding-characteristics of wheat germ agglutinin and Solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes. J. Control. Release 49(1), 27-37 (1997). (Pubitemid 27417898)
63. Pusztai A. Transport of proteins through the membranes of the adult gastro-intestinal tract -a potential for drug delivery? Adv. Drug Deliv. Rev. 3, 215-228 (1989). (Pubitemid 19146031)
64. Russell-Jones GJ, de Aizpurua HJ. Mucosal immunogens. In: Recent Advances in Mucosal Immunology. Mestecky J, McGhee JR, Bienenstock J, Ogra PL (Eds). Plenum Publishing Co, NY, USA (1987).
65. Bergman K-C, Russell-Jones GJ, Waldman RH. B Subunit of E. coli heat-labile enterotoxin enhances secretory IgA antibody response to oral influenza virus immunization in mice. Schweizerische Medizinische Wochenschrift. 121(Suppl. 40)/II, 28 (1991).
66. Bergmann K-C, Waldman RH, Bicak M, Russell-Jones GJ. Adjuvant effect of B-subunit of E.coli heat labile toxin on secretory antibody response to oral influenza virus immunization in mice. Allergologie 12, 294 (1989).
67. Lindner J, Geczy AF. Russell-Jones GJ. Identification of the site of uptake of the E. coli heat-labile enterotoxin, LTB. Scand. J. Immunol. 40, 564-572 (1994). (Pubitemid 24334025)
68. Pan YY. Li H. Zhao J et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249, 139-147 (2002).
69. Lambkin I, Pinilla C, Hamashin C et al. Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm. Res. 20(8), 1258-1266 (2003). (Pubitemid 36951851)
70. Lotter H, Khajawa F, Stanley SL Jr, Tannich E. Protection of gerbils from amebic liver abscess by vaccination with a 25-mer peptide derived from the cysteine-rich region of Entamoeba histolytica galactose-specific adherence lectin. Infect. Immun. 68, 4416-4421 (2000). (Pubitemid 30497706)
71. Mann BJ, Burkholder BV, Lockhart LA. Protection in a gerbil model of amebiasis by oral immunization with Salmonella expressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica. Vaccine 15(6-7), 659-663 (1997). (Pubitemid 27240481)
72. Beving DE, Soong CJ, Ravdin JI. Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Infect. Immun. 64(4), 1473-1476 (1996). (Pubitemid 26102422)
73. Gupta PN, Vyas SP. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf. B Biointerfaces 82(1), 118-125. (2011).
74. Chen H, Torchilin V, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 13(9), 1378-1383 (1996). (Pubitemid 26344985)
75. Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20(1-2), 208-217 (2001). (Pubitemid 32905334)
76. Russell-Jones GJ, Veitch H, Arthur L. Lectin-mediated transport of nanoparticles across Caco-2 and OK cells Int. J. Pharm. 190, 165-174 (1999). (Pubitemid 29509910)
77. Vandamme K, Vesna M, Eric C, Paul RJ, Chris V. Adjuvant effect of Gantrez®AN nanoparticles during oral vaccination of piglets against F4+enterotoxigenic Escherichia coli. Vet. Immunol. Immunopathol. 139(2-4), 148-155 (2011).
78. Mishra N, Tiwari S, Vaidya B, Agrawal GP, Vyas SP. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis Br. J. Drug Target. 19(1), 67-78 (2011).
79. Lavelle EC. Lectins and microparticles for enhanced oral vaccination. Methods 38, 84-89 (2006). (Pubitemid 43163467)
80. Manocha M, Pal PC, Chitralekha KT et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine, 23(48-49), 5599-5617 (2005). (Pubitemid 41608610)
81. Roth-Walter F, Schöll I, Untersmayr E et al. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 23(21), 2703-2710 (2005). (Pubitemid 40381262)
82. Clark MA, Hirst BH, Jepson MA. Lectin-mediated mucosal delivery of drugs and microparticles. Adv. Drug Deliv. Rev. 43(2-3), 207-223(2000).
83. Weissenböck A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J. Control Rel. 99, 383-392 (2004). (Pubitemid 39296907)
84. Widera A, Norouziyan F, Shen WC. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv. Drug Deliv. Rev. 55, 1439-1466 (2003). (Pubitemid 37464572)
85. Widera A, Bai Y, Shen WC. The transepithelial transport of a G-CSF-transferrin conjugate in Caco-2 cells and its myelopoietic effect in BDF1 mice. Pharm. Res. 21, 278-284 (2004). (Pubitemid 38221973)
86. Shah D, Shen WC. Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J. Pharm. Sci. 85, 1306-1311 (1996). (Pubitemid 27014185)
87. Xia CQ, Wang J, Shen WC. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 295, 594-600 (2000).
88. Kavimandan NJ, Losi E, Wilson JJ, Brodbelt JS, Peppas NA. Synthesis and characterization of insulin-transferrin conjugates. Bioconjug. Chem. 17, 1376-1384 (2006). (Pubitemid 44851480)
89. Xia CQ, Wang J. Shen WC. Hypoglycemic effect of insulin-transferrin conjugate on streptozoticin-induced diabetic rats. JPET, 295, 594-600 (2000).
90. Bai Y, Ann DK, Shen WC. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc. Natl Acad. Sci USA 102, 7292-7296 (2005). (Pubitemid 40696372)
91. Bai Y, Shen WC. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm. Res. 23, 2116-2121 (2006).
92. Chen X, Bai Y, Zaro JL, Shen WC. Design of an in vivo cleavable disulfide linker in recombinant fusion proteins. Biotechniques 49, 513-518 (2010).
93. Amet N, Lee HF, Shen WC. Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm. Res. 26, 523-528 (2009).
94. Lim CJ, Shen WC. Comparison of monomeric and oligomeric transferrin as potential carrier in oral delivery of protein drugs. J. Control Release 106, 273-86 (2005).
95. Amet N, Wang W, Shen WC. Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J. Control Release 141, 177-182 (2010).
96. Takeuchi T, Jyonotsuka T, Kamemori N et al. Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp. Physiol. 91, 1033-1040 (2006). (Pubitemid 44690815)
97. Takeuchi T, Jyonotsuka T, Kamemori N et al. Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp. Physiol. 91, 1033-1040 (2006). (Pubitemid 44690815)
98. Harada E, Itoh Y, Sitizyo K et al. Characteristic transport of lactoferrin from the intestinal lumen into the bile via blood in piglets. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 124, 321-327 (1999).
99. Kitagawa H, Yoshizawa Y, Yokoyama T et al. Persorption of bovine lactoferrin from the intestinal lumen into the systemic circulation via the portal vein and the mesenteric lymphatics in growing pigs. J. Vet. Med. Sci. 65, 567-572 (2003). (Pubitemid 41380126)
100. Harada E, Sugiyama A, Takeuchi T et al. Characteristic transfer of colostral components into cerebrospinal fluid via serum in neonatal pigs. Biol. Neonate. 76, 33-43 (1999). (Pubitemid 29281264)
101. Lee WJ, Farmer JL, Hilty M, Kim YB. The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect. Immun. 66, 1421-1426 (1998). (Pubitemid 128471499)
102. Talukdar MJ, Takeuchi T, Harada E. Characteristics of lactoferrin receptor in bovine intestine: higher binding activity to the epithelium overlying Peyer's patches. J. Vet. Med. A Physiol. Pathol. Clin. Med. 50, 123-131 (2003). (Pubitemid 41726276)
103. Wakabayashi H, Takakura N, Teraguchi S, Tamura Y. Lactoferrin feeding augments peritoneal macrophage activities in mice intraperitoneally injected with inactivated Candida albicans. Microbiol. Immunol. 47, 37-43 (2003). (Pubitemid 36119649)
104. Wakabayashi H, Takakura N, Yamauchi K, Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin. Vaccine Immunol. 13, 239-245 (2006). (Pubitemid 43383793)
105. Wang WP, Iigo M, Sato J et al., Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J. Cancer Res. 91, 1022-1027 (2000).
106. Yamauchi K, Wakabayashi H, Hashimoto S et al. Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv. Exp. Med. Biol. 443, 261-265 (1998). (Pubitemid 28432195)
107. Wang Y, Raghunadharao D, Raman G et al. Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24, 7095 (2006).
108. Hayes TG, Falchook GF, Varadhachary GR et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest. New Drugs 24(3), 233-240 (2006). (Pubitemid 43723899)
109. Jonasch E, Stadler WM, Bukowski RM et al. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 113(1), 72-77 (2008). (Pubitemid 351976388)
110. Roffler B, Fah A, Sauter SN et al. Intestinal morphology, epithelial cell proliferation, and absorptive capacity in neonatal calves fed milk-born insulin-like growth factor-1 or a colostrum extract. J. Dairy Sci. 86, 1797-1806 (2003). (Pubitemid 38995072)
111. Cox T, Mazurier J, Spik G, Montreuil J, Peters TJ. Iron binding proteins and influx of iron across the duodenal brush border: Evidence for specific lactotransferrin receptors in the human intestine. BBA 558, 120-128 (1979). (Pubitemid 10188255)
112. Khan S, Perkins AC, Frier M. Blackshaw PF, Leufkens P. Biodistribution of human lactoferrin in the gastrointestinal tract. In: Lactoferrin, Structure, Function and Applications. Shimazaki et al (Eds). Elsevier, Amsterdam, The Netherlands (2000).
113. Guo HY, Ibrahim SA, Zhang L et al. Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J. Nutr. 139, 958-964 (2008).
114. Blais A, Malet A, Mikogami T, Martin-Rouas C, Tome D. Oral bovine lactoferrin improves bone status of ovariectomized mice. Am. J. Physiol. Endocrinol. Metab. 296, E1281-E1288 (2009).
115. Artym J, Zimecki M, Paprocka M, Kruzel ML. Orally administered lactoferrin restores humoral immune response in immunocompromised mice. Immunol. Lett. 89, 9 -15 (2003). (Pubitemid 37304015)
116. Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H. Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25(10), 1961-1966 (2004). (Pubitemid 39405916)
117. Ushida Y, Sekine K, Kuhara T et al. Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J. Cancer Res. 90, 262-267 (1999). (Pubitemid 29164014)
118. Kuhara T, Iigo M, Itoh T et al. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer 38, 192-199 (2000). (Pubitemid 32762019)
119. Varadhachary A, Wolf JS, Petrak K et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int. J. Cancer 111, 398-403 (2004). (Pubitemid 38998820)
120. Nojima Y, Iguchi K, Suzuki Y, Sato A. The pH-dependent formation of PEGylated bovine lactoferrin by branched polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) active esters. Biol. Pharm. Bull. 32, 523-526 (2009).
121. Nojima Y, Suzuki Y, Iguchi K et al. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconj. Chem. 18, 2253-2259 (2008).
122. Spangler RS. Insulin administration via liposomes. Diabetes Care. 13(9), 911-922 (1990). (Pubitemid 20260733)
123. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol. Ther. 6(4), 510-517 (2004). (Pubitemid 39121378)
124. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current development. J. Diabetes Sci. Technol. 3(3), 562-527 (2009).
125. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes, 34(3), 222-234 (1985). (Pubitemid 15134779)
126. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes 41(9), 1042-1049 (1992).
127. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 124(1 Pt 2), 97-103 (1996). (Pubitemid 26011604)
128. Ruige JB, Assendelft WJ, Dekker JM et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 97(10), 996-1001 (1998). (Pubitemid 28125472)
129. Ruige JB, Assendelft WJ, Dekker JM et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 97(10), 996-1001 (1998). (Pubitemid 28125472)
130. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 37(12), 1595-1607 (1988). (Pubitemid 19004941)
131. Reaven GM. Syndrome X: 6 years later. J. Intern. Med. Suppl. 736, 13-22 (1994).
132. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14(3), 173-194 (1991).
133. Geho WB, Geho HC, Lau JR, Gana TJ. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J. Diabetes Sci. Technol. 3(6), 1451-1459 (2009).
134. Russell-Jones, D, Khan R. Insulin-associated weight gain in diabetes -causes, effects and coping strategies. Diabetes Obes. Metab. 9, 799-812 (2007). (Pubitemid 47555203)
135. Song SH, McIntyre SS, Shar H et al. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J. Clin. Endocrinol. Metab. 85, 4491-4499 (2000). (Pubitemid 32157623)
136. Buts JP, De Keyser N, Kolanowski J, Van Hoof F. Hormonal regulation of the rat small intestine: responsiveness of villus and crypt cells to insulin during the suckling period and unresponsiveness after weaning. Pediatr. Res. 27, 161-164 (1990). (Pubitemid 20044535)
137. Buts JP, De Keyser N, Marandi S et al. Expression of insulin receptors and of 60-kDa receptor substrate in rat mature and immature enterocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 273, G217-G226 (1997).
138. Buts JP, De Keyser N, Romain N et al. Response of rat immature enterocytes to insulin: regulation by receptor binding and endoluminal polyamine uptake. Gastroenterology 106, 58-68 (1994).
139. Buts JP, De Keyser N, Sokal EM, Marandi S. Oral insulin is biologically active on rat immature enterocytes. J. Pediatr. Gastroenterol. Nutr. 25, 230-232 (1997). (Pubitemid 27311392)
140. Fernandez-Moreno MD, Arilla E, Prieto JC. Insulin binding to rat intestinal epithelial cells following partial small-bowel resection. Biosci. Rep. 5, 445-450 (1986). (Pubitemid 17190854)
141. Fernández-Moreno MD, Fernández-González MA, Diaz-Juárez JL, López-Luna MP, Prieto JC. Interaction of insulin with small intestinal epithelial cells from developing rats. Biol. Neonate. 54(5), 289-293 (1988).
142. Fernandez-Moreno MD, Serrano-Rios M, Prieto JC. Identification of insulin receptors in epithelial cells from duodenum, jejunum, ileum, caecum, colon and rectum in the rat. Diabete. Metab. 13, 135-139 (1987). (Pubitemid 17071211)
143. Forgue-Lafitte ME, Marescot MR, Chamblier MC, Rosselin G. Evidence for the presence of insulin binding sites in isolated rat intestinal epithelial cells. Diabetologia 19(4), 373-378 (1980). (Pubitemid 10004006)
144. Georgiev IP, Georgieva TM, Pfaffl M, Hammon HM, Blum JW. Insulin-like growth factor and insulin receptors in intestinal mucosa of neonatal calves. J. Endocrinol. 176(1), 121-132 (2003). (Pubitemid 36163573)
145. Marandi S, de Keyser N, Saliez A et al. Insulin signal transduction in rat small intestine: role of MAP kinases in expression of mucosal hydrolases. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G229-G240 (2001).
146. King GL, Johnson S. Processing and transport of insulin by vascular endothelial cells. Effects of sulfonylureas on insulin receptors. Science 227, 1583-1586 (1985). (Pubitemid 15119466)
147. Ziv E, Bendayan M. Intestinal absorption of peptides through the enterocytes. Microsc. Res. Tech. 49, 346-352 (2000). (Pubitemid 30407770)
148. Bendayan M, Ziv E, Gingras D et al. Biochemical and morphocytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 37, 119-126 (1994). (Pubitemid 24042878)
149. Lin Y-H, Mi F-L, Chen C-T et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8, 146-141 (2007).
150. Lowman AM, Morishita M, Kajita M et al. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88, 933-937 (1999) (Pubitemid 29438959)
151. Rieux A, des Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Rel, 116, 1-27 (2006) (Pubitemid 44792295)
152. Carino GP, Mathiowitz E. Oral insulin delivery. Adv. Drug Deliv. Rev. 35, 249-257 (1999). (Pubitemid 29073617)
153. Ma Z, Lim TM, Lim LY. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats, Int. J. Pharm. 293, 271-280 (2005). (Pubitemid 40381099)
154. Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats J. Control. Rel. 117, 163-170 (2007). (Pubitemid 46161872)
155. Damgé C, Michel C, Aprahamian M, Couvreur P. Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J. Control. Rel. 13, 233-239 (1990). (Pubitemid 20313521)
156. Damgé C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37, 246-251 (1988). (Pubitemid 18066612)
157. Damgé C, Socha M, Ubrich N, Maincent P. Poly(e-caprolactone)/ eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes. J. Pharm. Sci. 99(2), 879-889 (2009).
158. Reis CP, Veiga FJ, Ribeiro AJ, Neufeld RJ, Damgé C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci. 97, 5290-5309 (2008).
159. Cournarie F, Auchere D, Chevenne D et al. Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats, Int. J. Pharm. 242, 325-328 (2002).
160. Michel C, Aprahamian M, Defontaine L, Courvreur P, Damge C. The effect of the site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmaco. 43, 1-5 (1991)
161. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. In vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54(4), 473-480 (2002). (Pubitemid 34308489)
162. Pinto-Alphandary H, Aboubakar M, Jaillard D, Couvreur P, Vauthier C. Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm. Res. 20(7), 1071-1084 (2003). (Pubitemid 36774279)
163. Kim B-Y, Jeong JH, Park K, Kim J-D. Bioadhesive interaction and hypoglycemic effect of insulin-loaded lectin-microparticle conjugates in oral insulin delivery system. J. Control. Rel. 102, 525-538 (2005). (Pubitemid 40170197)
164. Qi R, Ping QN. Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J. Microencapsul. 21, 37-45 (2004). (Pubitemid 38180746)
165. Morçöl T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJ. Calcium phosphate-PEGinsulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm. 277, 91-97 (2004). (Pubitemid 38670424)
166. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine 2, 743-749 (2007).
167. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Rel. 122, 141-150 (2007). (Pubitemid 47361403)
168. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Rel. 117, 421-429 (2007). (Pubitemid 46237606)
169. Mesiha MS, Lobel S, Salo DP, Khaleeva LD, Zekova NY. Biopharmaceutical study of insulin suppositories. Pharmazie 36(1), 29-32 (1981). (Pubitemid 11135274)
170. Mesiha MS, Ponnapula S, Plakogiannis F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha tocopherol dispersions. Int. J. Pharm. 249, 1-5 (2002). (Pubitemid 35333427)
171. Mesiha MS, El-Bitar HI. Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid. J. Pharm. Pharmacol. 33(11), 733-734 (1981). (Pubitemid 12254578)
172. Eaimtrakarn S, Rama Prasad YV, Ohno T et al. Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. J. Drug Target. 10, 255-260 (2002). (Pubitemid 34467295)
173. Heinemann L. Advanced technologies and treatment for diabetes. Int. J. Clin. Practice 65, 31-46 (2011).
174. Eldor R, Kidron M, Arbit E. Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. Diabetes Obes. Metab. 12, 219-223 (2010).
175. Kapitza C, Zijlstra E, Heinemann L et al. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care 33, 1288-1290 (2010).
176. Luzio SD, Dunsealth G, Lockett A et al. Glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes. Metab. 12, 82-87 (2010).
177. Hazra P, Adhikary L, Dave N et al. Development of a process to manufacture PEGylated orally bioavailable insulin. Biotechnol. Prog. 26, 1695-1704 (2010).
178. Dapergolas G. Gregoriadis G. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet 16, 824-827 (1976).
179. Patel HM, Ryman BE. Oral administration of insulin by encapsulation within liposomes. FEBS Lett. 62, 60-63 (1976)
180. Arrieta-Molero JF, Aleck K, Sinha MK et al. Orally administered liposome-entrapped insulin in diabetic animals. A critical assessment. Horm. Res. 16, 249-256 (1982). (Pubitemid 12047382)
181. Axt J, Sarrach D, Zipper J. Biopharmaceutical studies on phospholipid liposomes as carriers for the oral administration of insulin. Pharmazie 38, 246-248 (1983). (Pubitemid 13062168)
182. Spangler RS. Insulin administration via liposomes. Diabetes Care 13, 911-922 (1990). (Pubitemid 20260733)
183. Choudhari KB, Labhasetwar V, Dorle AK. Liposomes as a carrier for oral administration of insulin: effect of formulation factors. J. Microencapsul. 11, 319-325 (1994). (Pubitemid 24148441)
184. Muramatsu K, Maitani Y, Nagai T. Dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols and cholesterol as a carrier for the oral administration of insulin in rats. Biol. Pharm. Bull. 19, 1055-1058 (1996). (Pubitemid 26303367)
185. Iwanaga K, Ono S, Narioka K et al. Application of surface-coated lipsomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci. 88, 248-252 (1999). (Pubitemid 29084739)
186. Dapergolas G, Neerunjun ED, Gregoriadis G. Penetration of target areas in the rat by lipsome-associated bleomycin, glucose oxidase and insulin. FEBS Lett. 63, 235-239 (1976).
187. Katayama K, Kato Y, Onishi H, Nagai T, Machida Y. Double liposomes: hypoglycemic effects of liposomal insulin in normal rats. Drug Dev. Ind. Pharm. 29, 725-731 (2003). (Pubitemid 36899878)
188. 12 as a carrier for the oral delivery of insulin. Chem. Med. Chem. 2, 1717-1721 (2007).
189. Petrus AK, Fairchild TJ, Doyle RP. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew. Chem. Int. Ed. Engl. 48, 1022-1028 (2009).
190. Gordon Still J. Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev. 18(Suppl 1), S29-S37 (2002). (Pubitemid 34411298)
191. Marandi S, De Keyser N, Saliez A et al. Insulin signal transduction in rat small intestine: role of MAP kinases in expression of mucosal hydrolases. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G229-G240 (2001).
192. Ziv E, Kidron M, Raz I et al. Oral administration of insulin in solid form to nondiabetic and diabetic dogs. J. Pharm. Sci. 83, 792-794 (1994). (Pubitemid 24233751)
193. Farr SJ, McElduff A, Mather LE et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. 2, 185-197 (2000). (Pubitemid 30412817)
194. Henry RR, Mudaliar SRD, Howland WC III et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 26, 764-769 (2003). (Pubitemid 36929341)
195. Mastrandrea LD. Inhaled insulin, overview of a novel route of insulin administration. Vascular Health Risk Manag. 6, 47-58 (2010).
196. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled technosphere insulin. Ann. Pharmacother, 44, 1231-1239 (2010).
197. Rave K, de la Peña A, Tibaldi FS et al. 2007 AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 30(7), 1777-1782 (2007). (Pubitemid 47036351)
198. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27(6), 1318-1323 (2004). (Pubitemid 38679977)
199. Arthington JD, Cattell MB, Quigley JD, McCoy GC, Hurley WL. Passive immunoglobin transfer in newborn calves fed colostrum or spray-dried serum protein alone or as a supplement to colostrum of varying quality. J. Dairy. Sci. 83, 2834-2838 (2000).
200. Catrina M, Stirling A, Charleston B et al. Characterization of the porcine neonatal Fc receptor -potential use for trans-epithelial protein delivery Immunology 14, 542-553 (2005). (Pubitemid 40478148)
201. Kömüves LG, Heath JP. Uptake of maternal immunoglobulins in the enterocytes of suckling piglets: improved detection with a streptavidin-biotin bridge gold technique. J. Histochem. Cytochem. 40, 1637-1646 (1992).
202. Mayer B, Zolnai A, Frenyó LV et al. Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. Immunology 107(3), 288-296 (2002). (Pubitemid 35356948)
203. He W, Ladinsky MS, Huey-Tubman KE et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 455(7212), 542-546 (2008).
204. Liu L, Garcia AM, Santoro H et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J. Immunol. 178(8), 5390-5398 (2007). (Pubitemid 46595326)
205. Rodewald R, Abrahamson DR. Receptor-mediated transport of IgG across the intestinal epithelium of the neonatal rat. Ciba. Found. Symp. 92, 209-232 (1982).
206. Rodewald R. Intestinal transport of antibodies in the newborn rat. J. Cell Biol. 58(1), 189-211 (1973).
207. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J. Clin. Invest. 51(11), 2916-2927 (1972).
208. Mackenzie NM, Morris B, Morris R. Protein binding to brush borders of enterocytes from the jejunum of the neonatal rat. Biochim. Biophys. Acta. 755, 204-209 (1983). (Pubitemid 13153876)
209. Solari R, Morris B, Morris R. Kinetic studies on IgG transport by the jejunum of the neonatal rat. Biol. Neonate 46, 163-170 (1984). (Pubitemid 14036995)
210. Palombella VJ, Boudrea D, Kropp K et al. FcRn-mediated absorption of interferon alpha-Fc fusion protein in the lungs of non-human primates. Proc. Int. Control. Rel. Soc. (2003).
211. Bitonti AJ, Dumont JA, Low SC et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl Acad. Sci. USA 101, 9763-9768 (2004). (Pubitemid 38869310)
212. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 58(9-10), 1106-1118 (2006). (Pubitemid 44709269)
213. Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. Biodrugs 20, 151-160 (2006). (Pubitemid 43845335)
214. Dumont JA, Bitonti AJ, Clark D et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol. Med. Fall. 18(3), 294-303 (2005). (Pubitemid 41395731)
215. Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20, 1805-1813 (2005). (Pubitemid 40932360)
216. Spiekermann GM, Finn PW, Ward ES et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 196, 303-310 (2002). (Pubitemid 34875660)
217. Kuo TT, Baker K, Yoshida M et al. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 30(6), 777-789 (2010).
218. Kim K-J, Fandy TE, Lee VHL et al. Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L616-L622 (2004). (Pubitemid 39095919)
219. Li Z, Palaniyandi S, Zeng R et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl Acad. Sci. USA 108(11), 4388-4393 (2011).
220. Dickinson BL, Badizadegan J, Wu Z, Ahouse JC et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J. Clin. Invest. 104, 903-911 (1999). (Pubitemid 29536340)
221. Israel EJ, Taylor S, Wu Z et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92, 69-74 (1997). (Pubitemid 27380883)
222. Mezo AR, Sridhar V, Badger J, Sakorafas P, Nienaber V. X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn. J. Biol. Chem. 285(36), 27694-27701 (2010).
223. Shah U, Dickinson BL, Blumberg RS et al. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatr. Res. 53(2), 295-301 (2003). (Pubitemid 36177127)
224. Claypool SM, Dickinson BL, Wagner JS et al. Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor. Mol. Biol. Cell 15(4), 1746-1759 (2004). (Pubitemid 38401824)
225. Yoshida M, Masuda A, Kuo TT et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin. Immunopathol. 28(4), 397-403 (2006). (Pubitemid 44900578)
226. Yoshida M, Claypool SM, Wagner JS et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20(6), 769-783 (2004). (Pubitemid 38757446)
227. Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir. Med. 103(5), 661-669 (2009).
228. Ognenovski VM, Ojo TC, Fox DA. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J. Rheumatol. 35(11), 2279-2282 (2008).
229. Thomas JE, Taoka CR, Gibbs BT, Fraser SL. Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med. J. 65(1), 12-15 (2006).
230. Quintos-Macasa AM, Quinet R. Enbrel-induced interstitial lung disease. South. Med. J. 99(7), 783-784 (2006).
231. Roopenian DC, Sun VZ. Clinical ramifications of the MHC family Fc receptor FcRn. J. Clin. Immunol. 30, 790-797 (2010).
232. Kim J, Bronson CL, Hayton WL et al. Albumen turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G352-G360 (2006).
233. Leary HL Jr, Lecce JG. The preferential transport of immunoglobulin G by the small intestine of the neonatal piglet. J. Nutr. 109(3), 458-466 (1979). (Pubitemid 9175117)
234. 12 complex from guinea pig intestinal mucosa. J. Clin. Invest. 54, 733-439 (1974).
235. 12 receptor, cubilin, is a high affinity apolipoprotein A-1 receptor facilitating endocytosis of high-density lipoprotein. Nat. Med. 5, 656-661 (1999). (Pubitemid 29289429)
236. 12 receptor, cubilin: molecular characterization and chromosomal mapping of the gene to 10p within the autosomal recessive megaloblastic anemia (MGA1) region. Blood 91, 3593-3600 (1998). (Pubitemid 28225724)
237. 12-intrinsic factor complexes. Nature 464, 445-4448 (2010)
238. Ramasamy M, Alpers DH, Tiruppathi C, Seetharam B. Cobalamin release from intrinsic factor and transfer to transcobalamin II within the rat enterocyte. Am. J. Physiol. 257(5 Pt 1), G791-G797 (1989).
239. 12. Banerjee R (Ed.) Wiley, NY, USA (1999).
240. Quadros EV, Regec AL, Khan KM, Quadros E, Rothenberg SP. Transcobalamin II synthesized in the intestinal villi facilitates transfer of coblamin to the portal blood. Am. J. Physiol., 277, G161-G166 (1999). (Pubitemid 29352657)
241. 12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J. Biol. Chem. 273, 5235-5242 (1998). (Pubitemid 28108687)
242. 12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo. Int. J. Pharmacol., 145, 1-8 (1996). (Pubitemid 27062980)
243. 12 mediated oral delivery systems for granulocyte colony stimulating factor and erythropoietin. Bioconj. Chem. 6, 459-465 (1995).
244. 12 conjugates to deliver protein drugs by the oral route. Crit. Rev. Thera. Drug Carr. Sys. 16, 557-558 (1998)
245. 12 uptake system. Bioconj. Chem. 6, 34-42 (1995).
246. 12. Bioconj. Chem. 10, 1131-1136 (1999).
247. Russell-Jones GJ, Arthur L, Walker H. Vitamin B12-mediated transport of nanoparticles across Caco-2 cells Int. J. Pharm. 179, 247-255 (1999). (Pubitemid 29131434)
248. 12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules 6, 2462-2467 (2005). (Pubitemid 41388255)
249. 12-gantrez nanoparticles. Pharm. Res. 12, 2859-2868 (2008).
250. 12 bioconjugate pharmaceutical. Expert Opin. Drug Deliv. 8, 127-140 (2011).
251. 12 : a novel carrier for orally presented antigens. Proceed. Int. Symp. Control Rel. Bioact. Mater. 15, 142-143 (1988).
252. Russell-Jones GJ, McEwan JF, Galligher N, Wynn P. Development of analogues of growth hormone releasing peptides that are suitable for oral administration. Provisional patent, Animal Husbandry V App.#PR 5279 (2001).
253. 12 transport by transcobalamin. Proc. Natl Acad. Sci. USA 103, 4386-4391 (2006).
254. Gordon MM, Russell-Jones GJ, Alpers DH. Expression of functional intrinsic factor using recombinant baculovirus. Methods in Enzymol. 281, 255-261 (1997). (Pubitemid 27362465)
255. 12) pathway in the rat intestine. Pharm. Res. 17(7), 825-832 (2000). (Pubitemid 30666963)
256. Russell-Jones GJ. Nanoparticle delivery systems. Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development. Morishita M, Park K (Eds). CRS Press (Manuscript accepted) (2011).
257. Russell-Jones GJ. Himes R. Water-in-oil microemulsions for effective transdermal delivery of proteins. Expert Opin. Drug Deliv, 8, 537-546 (2011).
258. Himes R, Lee S, McMenigall K. Russell-Jones GJ. Reduction in Inflammation in the footpad of Carrageenan treated mice following the topical administration of anti-TNF molecules formulated in a Microemulsion. J. Control. Release 145(3), 210-213 (2010).
259. Himes R, Lee S, McMenigall K. Russell-Jones GJ. The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination. Vaccine 29(33), 5393-5398 (2011).